Domestic pharmaceutical company China Resources Sanjiu's intelligent manufacturing base in Shenzhen, Guangdong province. [Photo provided to chinadaily.com.cn]
Domestic pharmaceutical company China Resources Sanjiu reported solid gains during the 14th Five-Year Plan period (2021–25), driven by innovation, green development, and global vision.
The Shenzhen, Guangdong province-based company achieved steady growth in scale and profitability, with a compound annual growth rate of about 23.6 percent in revenue and 24.5 percent in total profit over the past three years, according to the company.
At the same time, CR Sanjiu continued to deliver robust returns to its shareholders. Since its listing, the firm has raised 1.67 billion yuan ($234.1 million) through stock issuance while distributing around 9.32 billion yuan in dividends — more than five times its actual fundraising.
Innovation has played a central role in its growth trajectory. The company's research and development investment rose from 581 million yuan in 2020 to 953 million yuan in 2024, marking a 64 percent increase. As of the first half of 2025, it had 205 research projects underway, covering key therapeutic areas such as cardiovascular and metabolic diseases, oncology, respiratory illnesses, neurology and psychiatry, gastroenterology, and dermatology, the company said.
In advancing sustainability goals, it has also embedded the dual carbon goals into its business operations. In 2025, its MSCI ESG rating was raised by two notches to A, underscored by strengthened green transition and sustainability capabilities.
CR Sanjiu's headquarters in Shenzhen, Guangdong province. [Photo provided to chinadaily.com.cn]
As a major player in strengthening the traditional Chinese medicine sector, the company has actively pursued strategic acquisitions. In January 2023, it acquired a 28 percent stake in Kunming, Yunnan province-based KPC Pharmaceuticals, completing the first A-share acquisition of its kind to qualify as a major asset restructuring.
In March 2025, it followed with another landmark deal, acquiring a 28 percent stake in Tianjin-based Tasly, marking the second such transaction during the 14th Five-Year Plan.
The three enterprises now form a complementary structure to build differentiated competitiveness through deepened collaboration. CR Sanjiu positions itself with consumer healthcare at the core to become an industry leader, while Tasly focuses on prescription drugs, and KPC Pharmaceuticals leverages its flagship TCM products to target the silver economy.
Looking ahead, as the company prepares to conclude the 14th Five-Year Plan and map out the 15th, CR Sanjiu said it will continue to shoulder its responsibility as a centrally administered State-owned enterprise, sharpen its core business focus, and accelerate innovation-driven transformation. By doing so, the drugmaker aims to offer "Chinese wisdom" and "Chinese solutions" for human well-being, it said.
